LILRB4 and acute myeloid leukemia: Additionally, in one case outside the context of a clinical trial (NCT05038800, terminated), a patient with refractory AML experienced acute myocarditis after receiving a single dose of mAb MK-0482, which may have been linked to unknown effects of LILRB4 inhibition on immune regulation [143, 147].